56 research outputs found
Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research
Cholangiocarcinoma (CCA) is a genetically and histologically complex disease with a highly dismal prognosis. A deeper understanding of the underlying cellular and molecular mechanisms of human CCA will increase our current knowledge of the disease and expedite the eventual development of novel therapeutic strategies for this fatal cancer. This endeavor is effectively supported by genetic mouse models, which serve as sophisticated tools to systematically investigate CCA pathobiology and treatment response. These in vivo models feature many of the genetic alterations found in humans, recapitulate multiple hallmarks of cholangiocarcinogenesis (encompassing cell transformation, preneoplastic lesions, established tumors and metastatic disease) and provide an ideal experimental setting to study the interplay between tumor cells and the surrounding stroma. This review is intended to serve as a compendium of CCA mouse models, including traditional transgenic models but also genetically flexible approaches based on either the direct introduction of DNA into liver cells or transplantation of pre-malignant cells, and is meant as a resource for CCA researchers to aid in the selection of the most appropriate in vivo model system
Single-institution experience in clinical trials during the COVID-19 pandemic in Spain: Not so bad after all?
The impact of the COVID-19 outbreak in Spain during
March-April 2020 has been unbalanced throughout
the different regions of the country. The alarm status
defined by the government on March 14, and still in
place at the time of this writing, has transformed the
country in different perspectives, including care of
patients with cancer.1 In many centers, clinical trial
activity was suspended, because it was not considered
a priority under the health care challenge of the
COVID-19 pandemic.2 Nevertheless, experimental
therapy is the only and/or best therapeutic option for
many patients with cancer
Genetic mouse models as in vivo tools for cholangiocarcinoma research
Cholangiocarcinoma (CCA) is a genetically and histologically complex disease with
a highly dismal prognosis. A deeper understanding of the underlying cellular and molecular
mechanisms of human CCA will increase our current knowledge of the disease and expedite
the eventual development of novel therapeutic strategies for this fatal cancer. This endeavor is
effectively supported by genetic mouse models, which serve as sophisticated tools to systematically
investigate CCA pathobiology and treatment response. These in vivo models feature many of the
genetic alterations found in humans, recapitulate multiple hallmarks of cholangiocarcinogenesis
(encompassing cell transformation, preneoplastic lesions, established tumors and metastatic disease)
and provide an ideal experimental setting to study the interplay between tumor cells and the
surrounding stroma. This review is intended to serve as a compendium of CCA mouse models,
including traditional transgenic models but also genetically flexible approaches based on either the
direct introduction of DNA into liver cells or transplantation of pre-malignant cells, and is meant as a
resource for CCA researchers to aid in the selection of the most appropriate in vivo model system
Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors
Checkpoint inhibitors have improved the survival of patients with advanced tumors and show
a manageable toxicity profile. However, auto-immune colitis remains a relevant side effect, and combinations of anti-PD1/PDL1 and anti-CTLA-4 increase its incidence and severity. Here, we report the case of
a 50-year-old patient diagnosed with stage IV cervical cancer that relapsed following radical surgery,
external radiation/brachytherapy and standard chemotherapy. She was subsequently treated with
Nivolumab and Ipilimumab combination and developed grade 2 colitis presenting a dissociation
between endoscopic and pathological findings. At cycle 10 the patient reported grade 3 diarrhea and
abdominal discomfort, without blood or mucus in the stools. Immunotherapy was withheld and
a colonoscopy was performed, showing normal mucosa in the entire colon. Puzzlingly, histologic
evaluation of randomly sampled mucosal biopsy of the distal colon showed an intense intraepithelial
lymphocyte infiltration with crypt loss and some regenerating crypts with a few apoptotic bodies set in
a chronically inflamed lamina propria, consistent with the microscopic diagnosis of colitis. Treatment
with methylprednisolone 2 mg/kg was initiated which led to a decrease in the number of stools to grade
1. Additional investigations to exclude other causes of diarrhea rendered negative results. The patient
experienced a major partial response and, following the resolution of diarrhea, she was re-challenged
again with immunotherapy, with the reappearance of grade 2 diarrhea, leading to permanent immunotherapy interruption. We conclude and propose that performing random colonic biopsies should be
considered in cases of immune checkpoint-associated unexplained diarrhea, even when colonoscopy
shows macroscopically normal colonic mucosa inflammatory lesions
Cytokines in clinical cancer immunotherapy
Cytokines are soluble proteins that mediate cell-to-cell communication. Based on the discovery of the potent anti-tumour activities of several pro-inflammatory cytokines in animal models, clinical research led to the approval of recombinant interferon-alpha and interleukin-2 for the treatment of several malignancies, even if efficacy was only modest. These early milestones in immunotherapy have been followed by the recent addition to clinical practice of antibodies that inhibit immune checkpoints, as well as chimeric antigen receptor T cells. A renewed interest in the anti-tumour properties of cytokines has led to an exponential increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs. These second-generation drugs under clinical development include known molecules with novel mechanisms of action, new targets, and fusion proteins that increase half-life and target cytokine activity to the tumour microenvironment or to the desired effector immune cells. In addition, the detrimental activity of immunosuppressive cytokines can be blocked by antagonistic antibodies, small molecules, cytokine traps or siRNAs. In this review, we provide an overview of the novel trends in the cytokine immunotherapy field that are yielding therapeutic agents for clinical trials
Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma
Background: Despite a potentially curative treatment, the prognosis after upfront surgery and adjuvant
chemotherapy for patients with resectable pancreatic ductal adenocarcinoma (PDAC) is poor. Modified
FOLFIRINOX (mFOLFIRINOX) is a cornerstone in the systemic treatment of PDAC, including the neoadjuvant setting. Pharmacokinetic-guided (PKG) dosing has demonstrated beneficial effects in other
tumors, but scarce data is available in pancreatic cancer.
Methods: Forty-six patients with resected PDAC after mFOLFIRINOX neoadjuvant approach and included
in an institutional protocol for anticancer drug monitoring were retrospectively analyzed. 5-Fluorouracil
(5-FU) dosage was adjusted throughout neoadjuvant treatment according to pharmacokinetic parameters and Irinotecan (CPT-11) pharmacokinetic variables were retrospectively estimated.
Results: By exploratory univariate analyses, a significantly longer progression-free survival was observed
for patients with either 5-FU area under the curve (AUC) above 28 mcgh/mL. In the multivariate analyses adjusted by age, gender, performance status and resectability
after stratification according to both pharmacokinetic parameters, the risk of progression was significantly reduced in patients with 5-FU AUC 28 mcgh/mL [HR ¼ 0.189, 95% CI 0.073e0.486, p ¼ 0.001].
Conclusions: Pharmacokinetically-guided dose adjustment of standard chemotherapy treatments might
improve survival outcomes in patients with pancreatic ductal adenocarcinoma
A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis
Surgically resectable synchronic and metachronic liver metastases of colon cancer have high risk of relapse in spite
of standard-of-care neoadjuvant and adjuvant chemotherapy regimens. Dendritic cell vaccines loaded with autologous
tumor lysates were tested for their potential to avoid or delay disease relapses (NCT01348256). Patients with surgically
amenable liver metastasis of colon adenocarcinoma (n = 19) were included and underwent neoadjuvant chemotherapy,
surgery and adjuvant chemotherapy. Fifteen patients with disease-free resection margins were randomized 1:1 to receive
two courses of four daily doses of dendritic cell intradermal vaccinations versus observation. The trial had been originally
designed to include 56 patients but was curtailed due to budgetary restrictions. Follow-up of the patients indicates a
clear tendency to fewer and later relapses in the vaccine arm (median disease free survival –DFS-) 25.26 months, 95% CI 8.
74-n.r) versus observation arm (median DFS 9.53 months, 95% CI 5.32–18.88)
Use of Machine-Learning Algorithms in Intensified Preoperative Therapy of Pancreatic Cancer to Predict Individual Risk of Relapse
Background: Although surgical resection is the only potentially curative treatment for pancreatic cancer (PC), long-term outcomes of this treatment remain poor. The aim of this study is to describe the feasibility of a neoadjuvant treatment with induction polychemotherapy (IPCT) followed by chemoradiation (CRT) in resectable PC, and to develop a machine-learning algorithm to predict risk of relapse.
Methods: Forty patients with resectable PC treated in our institution with IPCT (based on mFOLFOXIRI, GEMOX or GEMOXEL) followed by CRT (50 Gy and concurrent Capecitabine) were retrospectively analyzed. Additionally, clinical, pathological and analytical data were collected in order to perform a 2-year relapse-risk predictive population model using machine-learning techniques.
Results: A R0 resection was achieved in 90% of the patients. After a median follow-up of 33.5 months, median progression-free survival (PFS) was 18 months and median overall survival (OS) was 39 months. The 3 and 5-year actuarial PFS were 43.8% and 32.3%, respectively. The 3 and 5-year actuarial OS were 51.5% and 34.8%, respectively. Forty-percent of grade 3-4 IPCT toxicity, and 29.7% of grade 3 CRT toxicity were reported. Considering the use of granulocyte colony-stimulating factors, the number of resected lymph nodes, the presence of perineural invasion and the surgical margin status, a logistic regression algorithm predicted the individual 2-year relapse-risk with an accuracy of 0.71 (95% confidence interval [CI] 0.56-0.84, p = 0.005). The model-predicted outcome matched 64% of the observed outcomes in an external dataset.
Conclusion: An intensified multimodal neoadjuvant approach (IPCT + CRT) in resectable PC is feasible, with an encouraging long-term outcome. Machine-learning algorithms might be a useful tool to predict individual risk of relapse. A small sample size and therapy heterogeneity remain as potential limitations
Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis
- …